Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $5,906,802 | $6,064 | $4,644 | $3,707 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $40 | $0 | $51 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $54 | $162 | $100 |
| Total Curr. Assets | $5,906,802 | $6,158 | $4,805 | $3,858 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $198,409 | $0 | $0 | $0 |
| Total Assets | $6,105,211 | $6,158 | $4,805 | $3,858 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $2,468,175 | $2,592 | $2,494 | $3,243 |
| Total Curr. Liab. | $2,468,175 | $2,592 | $2,494 | $3,243 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $2,468,175 | $2,592 | $2,494 | $3,243 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,800 | $1 | $22 | $17 |
| Retained Earnings | -$73,710,218 | -$71,717 | -$69,471 | -$67,322 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $77,345,454 | $75,282 | $71,760 | $67,920 |
| Total Equity | $3,637,036 | $3,566 | $2,311 | $615 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $6,105,211 | $6,158 | $4,805 | $3,858 |
| Net Debt | -$5,906,802 | -$6,064 | -$4,644 | -$3,707 |